Laske Christoph, Stransky Elke, Fritsche Andreas, Eschweiler Gerhard W, Leyhe Thomas
Dept. of Psychiatry and Psychotherapy, University of Tuebingen, Osianderstr. 24, 72076, Tuebingen, Germany.
Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. doi: 10.1007/s00406-008-0838-3. Epub 2008 Sep 19.
Hypercortisolemia and increased levels of hyperphosphorylated tau proteins in cerebrospinal fluid (CSF) are common features with pathogenic relevance in Alzheimer;s disease (AD). Experimental studies point to an influence of cortisol on Abeta and tau pathology in AD. Association of both parameters have not yet been described in a sample of AD patients. In the present study, serum levels of cortisol were determined in 26 patients with mild AD dementia and 20 age-matched healthy elderly controls by ELISA. In addition, we measured in AD patients CSF levels of cortisol, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau 181), tau protein phosphorylated at threonine 231 (P-tau 231) and beta-Amyloid (Abeta) 1-42 and determined T-tau/Abeta 1-42 ratios in CSF. We found in AD patients significantly increased cortisol serum levels (551.4 +/- 146.1 nmol/l; P = 0.002) as compared to healthy controls (435.3 +/- 83.9 nmol/l). In AD patients, cortisol serum levels were significantly inversely correlated with T-tau (r = -0.496; P = 0.01), P-tau 181 (r = -0.558; P = 0.003) and P-tau 231 (-0.500; P = 0.009) protein levels and T-tau/Abeta 1-42 ratios (r = -0.450; P = 0.021) in CSF. In addition, cortisol serum levels showed a trend of positive correlation with Abeta 1-42 CSF levels (r = 0.386; P = 0.052). However, no significant correlations of cortisol serum with CSF levels as well as cortisol CSF levels with CSF biomarkers could be detected in AD patients. In conclusion, our results show that increased cortisol serum but not CSF levels are associated with minor signs of AD pathology in CSF, indicating a putative neuroprotective effect of moderately elevated cortisol serum levels in patients with mild AD dementia.
高皮质醇血症以及脑脊液(CSF)中过度磷酸化tau蛋白水平升高是阿尔茨海默病(AD)中具有致病相关性的常见特征。实验研究表明皮质醇对AD中的β淀粉样蛋白(Aβ)和tau病理有影响。在AD患者样本中尚未描述这两个参数之间的关联。在本研究中,通过酶联免疫吸附测定法(ELISA)测定了26例轻度AD痴呆患者和20名年龄匹配的健康老年对照者的血清皮质醇水平。此外,我们还测量了AD患者脑脊液中皮质醇、总tau(T-tau)、苏氨酸181位点磷酸化的tau(P-tau 181)、苏氨酸231位点磷酸化的tau蛋白(P-tau 231)以及β淀粉样蛋白(Aβ)1-42的水平,并确定了脑脊液中T-tau/Aβ 1-42的比值。我们发现,与健康对照者(435.3±83.9 nmol/l)相比,AD患者的血清皮质醇水平显著升高(551.4±146.1 nmol/l;P = 0.002)。在AD患者中,血清皮质醇水平与脑脊液中的T-tau(r = -0.496;P = 0.01)、P-tau 181(r = -0.558;P = 0.003)和P-tau 231(-0.500;P = 0.009)蛋白水平以及T-tau/Aβ 1-42比值(r = -0.450;P = 0.021)显著负相关。此外,血清皮质醇水平与脑脊液中Aβ 1-42水平呈正相关趋势(r = 0.386;P = 0.052)。然而,在AD患者中未检测到血清皮质醇与脑脊液水平以及脑脊液皮质醇水平与脑脊液生物标志物之间的显著相关性。总之,我们的结果表明,血清皮质醇水平升高而非脑脊液皮质醇水平升高与脑脊液中AD病理的轻微迹象相关,这表明轻度AD痴呆患者中适度升高的血清皮质醇水平可能具有神经保护作用。